Equities analysts expect Haemonetics Co. (NYSE:HAE) to post $0.59 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Haemonetics’ earnings, with the lowest EPS estimate coming in at $0.57 and the highest estimate coming in at $0.62. Haemonetics posted earnings of $0.62 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 4.8%. The business is expected to announce its next quarterly earnings results on Tuesday, February 5th.
According to Zacks, analysts expect that Haemonetics will report full-year earnings of $2.33 per share for the current year, with EPS estimates ranging from $2.30 to $2.37. For the next year, analysts expect that the firm will post earnings of $3.04 per share, with EPS estimates ranging from $2.61 to $3.40. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Haemonetics.
Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.02. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company had revenue of $241.58 million during the quarter, compared to analyst estimates of $233.44 million. During the same period in the previous year, the business earned $0.48 earnings per share. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year.
Several research analysts recently issued reports on HAE shares. Barrington Research reiterated a “buy” rating and issued a $127.00 target price on shares of Haemonetics in a research report on Friday, October 5th. TheStreet lowered shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Finally, Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price for the company in a research report on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $113.20.
NYSE:HAE traded down $2.03 during midday trading on Monday, hitting $103.17. The company had a trading volume of 609,233 shares, compared to its average volume of 444,407. Haemonetics has a 52-week low of $56.23 and a 52-week high of $117.56. The firm has a market capitalization of $5.44 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 3.61 and a beta of 1.09. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.92.
In other Haemonetics news, SVP Jacqueline Scanlan sold 4,890 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $112.19, for a total transaction of $548,609.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William P. Mr. Burke sold 841 shares of the company’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,653 shares of company stock valued at $6,973,391. Company insiders own 1.04% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans boosted its holdings in shares of Haemonetics by 5.9% during the third quarter. Thrivent Financial for Lutherans now owns 12,591 shares of the medical instruments supplier’s stock worth $1,443,000 after purchasing an additional 696 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Haemonetics by 2.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 33,558 shares of the medical instruments supplier’s stock worth $3,009,000 after purchasing an additional 810 shares during the period. Xact Kapitalforvaltning AB boosted its holdings in shares of Haemonetics by 14.7% during the third quarter. Xact Kapitalforvaltning AB now owns 8,595 shares of the medical instruments supplier’s stock worth $985,000 after purchasing an additional 1,100 shares during the period. GAM Holding AG boosted its holdings in shares of Haemonetics by 22.4% during the second quarter. GAM Holding AG now owns 6,343 shares of the medical instruments supplier’s stock worth $569,000 after purchasing an additional 1,159 shares during the period. Finally, Riverhead Capital Management LLC boosted its holdings in shares of Haemonetics by 27.8% during the third quarter. Riverhead Capital Management LLC now owns 5,971 shares of the medical instruments supplier’s stock worth $684,000 after purchasing an additional 1,300 shares during the period. Institutional investors and hedge funds own 98.37% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Story: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.